Cargando…

A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report

BACKGROUND: Human hepcidin, produced by hepatocytes, regulates intestinal iron absorption, iron recycling by macrophages, and iron release from hepatic storage. Recent studies indicate that hepcidin deficiency is the underlying cause of the most known form of hereditary hemochromatosis. CASE PRESENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamada, Yuki, Hirano, Eiichi, Sugimoto, Koji, Hanada, Keizo, Kaku, Taiichi, Manda, Naoki, Tsuchida, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784004/
https://www.ncbi.nlm.nih.gov/pubmed/35065677
http://dx.doi.org/10.1186/s13256-021-03230-5
_version_ 1784638653341892608
author Hamada, Yuki
Hirano, Eiichi
Sugimoto, Koji
Hanada, Keizo
Kaku, Taiichi
Manda, Naoki
Tsuchida, Kenichi
author_facet Hamada, Yuki
Hirano, Eiichi
Sugimoto, Koji
Hanada, Keizo
Kaku, Taiichi
Manda, Naoki
Tsuchida, Kenichi
author_sort Hamada, Yuki
collection PubMed
description BACKGROUND: Human hepcidin, produced by hepatocytes, regulates intestinal iron absorption, iron recycling by macrophages, and iron release from hepatic storage. Recent studies indicate that hepcidin deficiency is the underlying cause of the most known form of hereditary hemochromatosis. CASE PRESENTATION: A 44-year-old Asian man who developed type 2 diabetes mellitus had elevated serum ferritin levels (10,191 ng/mL). Liver biopsy revealed remarkable iron deposition in the hepatocytes and relatively advanced fibrosis (F3). Chromosomal analysis confirmed the presence of transferrin receptor type 2 mutations (c.1100T>G, c.2008_9delAC, hereditary hemochromatosis type 3 analyzed by Kawabata). The patient received intravenous infusions of Laennec (672 mg/day, three times/week) or oral administration with Porcine (3.87 g/day) for 84 months as an alternative to repeated phlebotomy. At the end of the treatment period, serum ferritin level decreased to 428.4 ng/mL (below the baseline level of 536.8 ng/mL). Hemoglobin A1c levels also improved after treatment with the same or lower dose of insulin (8.8% before versus 6.8% after). Plural liver biopsies revealed remarkable improvements in the grade of iron deposition and fibrosis (F3 before versus F1 after) of the liver tissue. CONCLUSION: The discovery of hepcidin and its role in iron metabolism could lead to novel therapies for hereditary hemochromatosis. Laennec (parenteral) and Porcine (oral), which act as hepcidin inducers, actually improved iron overload in this hereditary hemochromatosis patient, without utilizing sequential phlebotomy. This suggests the possibility of not only improving the prognosis of hereditary hemochromatosis (types 1, 2, and 3) but also ameliorating complications, such as type 2 diabetes, liver fibrosis, and hypogonadism. Laennec and Porcine can completely replace continuous venesection in patients with venesection and may improve other iron-overloading disorders caused by hepcidin deficiency.
format Online
Article
Text
id pubmed-8784004
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87840042022-01-24 A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report Hamada, Yuki Hirano, Eiichi Sugimoto, Koji Hanada, Keizo Kaku, Taiichi Manda, Naoki Tsuchida, Kenichi J Med Case Rep Case Report BACKGROUND: Human hepcidin, produced by hepatocytes, regulates intestinal iron absorption, iron recycling by macrophages, and iron release from hepatic storage. Recent studies indicate that hepcidin deficiency is the underlying cause of the most known form of hereditary hemochromatosis. CASE PRESENTATION: A 44-year-old Asian man who developed type 2 diabetes mellitus had elevated serum ferritin levels (10,191 ng/mL). Liver biopsy revealed remarkable iron deposition in the hepatocytes and relatively advanced fibrosis (F3). Chromosomal analysis confirmed the presence of transferrin receptor type 2 mutations (c.1100T>G, c.2008_9delAC, hereditary hemochromatosis type 3 analyzed by Kawabata). The patient received intravenous infusions of Laennec (672 mg/day, three times/week) or oral administration with Porcine (3.87 g/day) for 84 months as an alternative to repeated phlebotomy. At the end of the treatment period, serum ferritin level decreased to 428.4 ng/mL (below the baseline level of 536.8 ng/mL). Hemoglobin A1c levels also improved after treatment with the same or lower dose of insulin (8.8% before versus 6.8% after). Plural liver biopsies revealed remarkable improvements in the grade of iron deposition and fibrosis (F3 before versus F1 after) of the liver tissue. CONCLUSION: The discovery of hepcidin and its role in iron metabolism could lead to novel therapies for hereditary hemochromatosis. Laennec (parenteral) and Porcine (oral), which act as hepcidin inducers, actually improved iron overload in this hereditary hemochromatosis patient, without utilizing sequential phlebotomy. This suggests the possibility of not only improving the prognosis of hereditary hemochromatosis (types 1, 2, and 3) but also ameliorating complications, such as type 2 diabetes, liver fibrosis, and hypogonadism. Laennec and Porcine can completely replace continuous venesection in patients with venesection and may improve other iron-overloading disorders caused by hepcidin deficiency. BioMed Central 2022-01-23 /pmc/articles/PMC8784004/ /pubmed/35065677 http://dx.doi.org/10.1186/s13256-021-03230-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Hamada, Yuki
Hirano, Eiichi
Sugimoto, Koji
Hanada, Keizo
Kaku, Taiichi
Manda, Naoki
Tsuchida, Kenichi
A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report
title A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report
title_full A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report
title_fullStr A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report
title_full_unstemmed A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report
title_short A farewell to phlebotomy—use of placenta-derived drugs Laennec and Porcine for improving hereditary hemochromatosis without phlebotomy: a case report
title_sort farewell to phlebotomy—use of placenta-derived drugs laennec and porcine for improving hereditary hemochromatosis without phlebotomy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784004/
https://www.ncbi.nlm.nih.gov/pubmed/35065677
http://dx.doi.org/10.1186/s13256-021-03230-5
work_keys_str_mv AT hamadayuki afarewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT hiranoeiichi afarewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT sugimotokoji afarewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT hanadakeizo afarewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT kakutaiichi afarewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT mandanaoki afarewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT tsuchidakenichi afarewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT hamadayuki farewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT hiranoeiichi farewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT sugimotokoji farewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT hanadakeizo farewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT kakutaiichi farewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT mandanaoki farewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport
AT tsuchidakenichi farewelltophlebotomyuseofplacentaderiveddrugslaennecandporcineforimprovinghereditaryhemochromatosiswithoutphlebotomyacasereport